We're pleased to share that Axel Hoos, M.D., Ph.D., a member of the CRI Scientific Advisory Council, co-director of our Cancer Immunotherapy Consortium Leadership Committee, and vice president for oncology research and development at GlaxoSmithKline, will be the chair and industry keynote for the Immuno-Oncology 360° Conference, which will be held on June 29-30, 2015, at the Faculty House at Columbia University in New York, NY.
Over the past five years, the FDA has approved four new immunotherapies for prostate cancer, melanoma, and lung cancer, and more are going to come in the next five years. These include drugs like checkpoint inhibitors, chimeric antigen receptor (CAR) T cell therapies, cancer vaccines, and immune modulators, and combinations will be a key component. With the growth of cancer immunotherapy drug development on the rise, the approaches for business are undergoing a rapid change to keep up. The Immuno-Oncology 360° Conference will bring together business and clinical development strategies, as well as scientific updates, to accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies.
“We are undergoing a radical change in cancer treatment, and the biopharma industry needs to gain information that will be beneficial for industry and patients,” said Axel Hoos, M.D., Ph.D. “The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have on clinical designs and recruitment procedures.”
Axel Hoos, M.D., Ph.D., will give the keynote address, titled “The Future of Immuno-Oncology,” on June 30.
Learn more at www.theconferenceforum.org/conferences/immuno-oncology-360/overview.